What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Immune system
His scientific interests lie mostly in Immunology, Ipilimumab, Internal medicine, Melanoma and Immunotherapy.
In most of his Immunology studies, his work intersects topics such as Cytotoxic T cell.
His Ipilimumab research incorporates themes from Placebo, CTLA-4, Clinical trial and Blocking antibody.
His Internal medicine study incorporates themes from Gastroenterology, Surgery and Oncology.
His biological study spans a wide range of topics, including Pembrolizumab and Hazard ratio.
His Melanoma research incorporates elements of Survival rate, Cohort, Pathology, Proportional hazards model and Metastasis.
His most cited work include:
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. (10003 citations)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (4552 citations)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (4552 citations)
What are the main themes of his work throughout his whole career to date?
Jedd D. Wolchok mainly investigates Internal medicine, Immunology, Melanoma, Ipilimumab and Oncology.
His Cancer, Clinical trial and Advanced melanoma study in the realm of Internal medicine interacts with subjects such as In patient.
His Immunology study often links to related topics such as Cytotoxic T cell.
His Melanoma research includes themes of Pembrolizumab, Phases of clinical research, Gastroenterology, Pathology and DNA vaccination.
His work in Ipilimumab addresses issues such as Nivolumab, which are connected to fields such as Combination therapy.
His Immunotherapy research is multidisciplinary, incorporating elements of CTLA-4 and Cancer research.
He most often published in these fields:
- Internal medicine (44.78%)
- Immunology (49.89%)
- Melanoma (45.78%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (27.67%)
- Internal medicine (44.78%)
- Immunotherapy (33.22%)
In recent papers he was focusing on the following fields of study:
Jedd D. Wolchok focuses on Cancer research, Internal medicine, Immunotherapy, Oncology and Melanoma.
Jedd D. Wolchok has researched Cancer research in several fields, including Immune checkpoint, Blockade and T cell, CD8, Immune system.
His study with Immune system involves better knowledge in Immunology.
In general Internal medicine study, his work on Nivolumab, Ipilimumab, Cancer and Clinical trial often relates to the realm of In patient, thereby connecting several areas of interest.
Jedd D. Wolchok has included themes like Placebo and Hazard ratio in his Ipilimumab study.
His Melanoma study combines topics from a wide range of disciplines, such as Discontinuation, Radiation therapy, Proportional hazards model and Cohort.
Between 2017 and 2021, his most popular works were:
- Cancer immunotherapy using checkpoint blockade (1674 citations)
- Cancer immunotherapy using checkpoint blockade (1674 citations)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (1122 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Internal medicine, Immunotherapy, Cancer research, Oncology and Melanoma.
His study in Ipilimumab, Nivolumab, Clinical trial, Pembrolizumab and Cancer is done as part of Internal medicine.
He focuses mostly in the field of Ipilimumab, narrowing it down to matters related to Hazard ratio and, in some cases, Placebo.
His Cancer research research integrates issues from Tumor microenvironment, Immune system, Blockade, Cancer immunotherapy and CTLA-4.
His work in the fields of Lung cancer overlaps with other areas such as Text mining.
Jedd D. Wolchok integrates many fields, such as Melanoma and In patient, in his works.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
